Stock Analysis on Net
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Celgene Corp., adjusted current assets

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Current assets 9,067 14,892 10,868 9,401 9,713
Adjustments
Add: Allowance for doubtful accounts 16 16 15 18 21
Less: Current deferred tax assets1 — — — — 12
After Adjustment
Adjusted current assets 9,083 14,908 10,883 9,419 9,722

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Current deferred tax assets. See details »


The asset profile exhibits significant volatility between 2014 and 2018, characterized by a period of growth followed by a sharp contraction. While current assets remained relatively stable between 2014 and 2015, a marked increase occurred through 2017, reaching a peak of 14,892 million US dollars. This peak was followed by a substantial reduction in 2018, bringing the balance to 9,067 million US dollars, the lowest level recorded during the analyzed timeframe.

Correlation between Reported and Adjusted Assets
A nearly identical trend is observed between current assets and adjusted current assets. The two metrics move in lockstep, indicating that the adjustments made to the figures are marginal and do not materially alter the overall financial trajectory of the current asset base.
Analysis of Adjustment Magnitude
The variance between reported current assets and adjusted current assets remains consistently low, ranging from 9 million to 18 million US dollars annually. These adjustments represent a negligible percentage of the total assets, suggesting that the underlying modifications are minor accounting corrections or specific reclassifications that do not impact the broader liquidity position.
Peak and Contraction Cycle
The most notable movement occurred between 2017 and 2018, where current assets decreased by approximately 39%. This sharp decline follows a significant 37% increase from 2016 to 2017, highlighting a period of high instability in short-term asset holdings.

AI Ask an analyst for more


Adjustments to Total Assets

Celgene Corp., adjusted total assets

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Total assets 35,480 30,141 28,086 27,053 17,340
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 375 209 191 206 197
Add: Allowance for doubtful accounts 16 16 15 18 21
Less: Current deferred tax assets2 — — — — 12
Less: Non-current deferred tax assets (included in Other non-current assets)3 24 23 138 66 57
After Adjustment
Adjusted total assets 35,847 30,343 28,154 27,212 17,489

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Current deferred tax assets. See details »

3 Non-current deferred tax assets (included in Other non-current assets). See details »


A consistent upward trajectory in both total assets and adjusted total assets is observed over the five-year period from 2014 to 2018. Total assets grew from 17,340 million US$ to 35,480 million US$, representing a cumulative increase of approximately 104.6%. The most significant expansion occurred between 2014 and 2015, where total assets increased by 56.0%, indicating a period of substantial capital growth or acquisition activity.

Asset Growth Patterns
Following the sharp increase in 2015, the growth rate stabilized between 2016 and 2017, with annual increases of 3.8% and 7.3% respectively. A renewed acceleration is evident in 2018, with assets rising by 17.7% to reach a period high of 35,480 million US$.
Adjusted Total Assets Analysis
Adjusted total assets mirror the growth pattern of reported total assets, ending the period at 35,847 million US$. The adjusted figures are consistently higher than the reported total assets for every year analyzed, suggesting a systematic upward adjustment to the asset base for reporting or analytical purposes.
Variance and Adjustment Magnitude
The absolute difference between total assets and adjusted total assets remained relatively small compared to the overall asset base. The adjustment amount fluctuated from a low of 68 million US$ in 2016 to a high of 367 million US$ in 2018. In percentage terms, the adjustment ranged from approximately 0.24% of total assets in 2016 to 1.03% in 2018, indicating that while adjustments were present, they did not materially distort the overall asset growth trend.

AI Ask an analyst for more


Adjustments to Current Liabilities

Celgene Corp., adjusted current liabilities

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Current liabilities 4,057 2,987 2,959 1,969 2,112
Adjustments
Less: Current deferred tax liabilities1 — — — — 131
Less: Current portion of deferred revenue 73 75 55 61 29
After Adjustment
Adjusted current liabilities 3,984 2,912 2,904 1,908 1,952

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Current deferred tax liabilities. See details »


Current liabilities exhibited an increasing trend over the five-year period, while adjusted current liabilities mirrored this pattern, though with differing magnitudes. A comparison of the two figures reveals adjustments consistently reducing the reported value of current liabilities.

Overall Trend
Both current liabilities and adjusted current liabilities generally increased from 2014 to 2018. Current liabilities rose from US$2,112 million to US$4,057 million, representing a substantial increase over the period. Adjusted current liabilities also increased, moving from US$1,952 million to US$3,984 million.
Adjustment Magnitude
The difference between current liabilities and adjusted current liabilities remained relatively stable in absolute terms. In 2014, the adjustment was US$160 million (US$2,112 - US$1,952). By 2018, the adjustment was US$73 million (US$4,057 - US$3,984). This suggests a decreasing trend in the absolute amount of adjustments made to current liabilities.
Year-over-Year Changes
From 2014 to 2015, both figures decreased slightly. However, from 2015 to 2016, a significant increase is observed in both current and adjusted current liabilities. The growth rate slowed between 2016 and 2017, and then accelerated again between 2017 and 2018. The adjustments made in 2016, 2017, and 2018 were minimal, indicating a smaller impact from the adjustments in those years.
Proportional Adjustment
The proportional adjustment (Adjusted Current Liabilities / Current Liabilities) remained relatively consistent, fluctuating between approximately 92% and 98% throughout the period. This indicates that the adjustments consistently reduced current liabilities by a similar percentage each year.

The consistent adjustments to current liabilities suggest the presence of items that are classified as current liabilities for reporting purposes but are adjusted for internal analytical purposes. The decreasing absolute adjustment amount may indicate a change in the nature or volume of these items.

AI Ask an analyst for more


Adjustments to Total Liabilities

Celgene Corp., adjusted total liabilities

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Total liabilities 29,319 23,220 21,486 21,134 10,815
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 375 209 191 206 197
Less: Current deferred tax liabilities2 — — — — 131
Less: Non-current deferred tax liabilities3 2,753 1,327 — 378 556
Less: Deferred revenue 146 109 83 91 56
After Adjustment
Adjusted total liabilities 26,795 21,993 21,594 20,872 10,269

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Current deferred tax liabilities. See details »

3 Non-current deferred tax liabilities. See details »


A sustained upward trend in total liabilities is observed between 2014 and 2018, characterized by a significant expansion in the company's financial obligations. The most substantial growth occurred between 2014 and 2015, where total liabilities nearly doubled, followed by a consistent year-over-year increase through the end of the period.

Liability Expansion Analysis
Total liabilities rose from 10,815 million US$ in 2014 to 29,319 million US$ in 2018, representing a total increase of approximately 171%. Adjusted total liabilities followed a similar trajectory, increasing from 10,269 million US$ to 26,795 million US$ over the same five-year interval.
Adjustment Variance Trends
The divergence between total liabilities and adjusted total liabilities widened notably over time. In 2014, the difference was 546 million US$, and by 2018, this gap increased to 2,524 million US$. This indicates that the adjustments applied to total liabilities became more material as the absolute volume of debt grew.
Comparative Growth Dynamics
While both metrics trended upward, a distinct divergence emerged in the final year of the period. Between 2017 and 2018, total liabilities increased by 6,099 million US$, whereas adjusted total liabilities increased by a smaller margin of 4,802 million US$, suggesting an increase in the proportion of non-adjusted liability components.

AI Ask an analyst for more


Adjustments to Stockholders’ Equity

Celgene Corp., adjusted stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Stockholders’ equity 6,161 6,921 6,599 5,919 6,525
Adjustments
Less: Net deferred tax asset (liability)1 (2,729) (1,304) 138 (312) (619)
Add: Allowance for doubtful accounts 16 16 15 18 21
Add: Deferred revenue 146 109 83 91 56
After Adjustment
Adjusted stockholders’ equity 9,052 8,350 6,560 6,340 7,220

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Net deferred tax asset (liability). See details »


An analysis of the equity position from 2014 to 2018 reveals a diverging trend between reported stockholders' equity and adjusted stockholders' equity. While the reported figures experienced volatility, the adjusted values demonstrated a significant growth trajectory in the latter half of the period.

Reported Stockholders' Equity Trends
The reported stockholders' equity exhibited a non-linear progression, decreasing from 6,525 million in 2014 to 5,919 million in 2015. A recovery phase followed, with values peaking at 6,921 million in 2017 before declining to 6,161 million by the end of 2018.
Adjusted Stockholders' Equity Trends
Adjusted stockholders' equity followed a more aggressive growth trajectory after 2015. Following a decrease to 6,340 million in 2015, the adjusted equity increased consistently, rising to 8,350 million in 2017 and reaching 9,052 million in 2018.
Variance and Divergence Analysis
A widening gap is observed between the reported and adjusted equity figures over the five-year period. In 2016, the two metrics were nearly aligned, with only a marginal difference of 39 million. However, a sharp divergence occurred between 2017 and 2018; by the end of 2018, adjusted stockholders' equity exceeded reported equity by 2,891 million, indicating that the adjustments to the equity account became substantially more significant over time.

AI Ask an analyst for more


Adjustments to Capitalization Table

Celgene Corp., adjusted capitalization table

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Short-term borrowings and current portion of long-term debt 501 — 501 — 606
Long-term debt, net of discount, excluding current portion 19,769 15,838 13,789 14,250 6,266
Total reported debt 20,270 15,838 14,289 14,250 6,872
Stockholders’ equity 6,161 6,921 6,599 5,919 6,525
Total reported capital 26,431 22,759 20,889 20,169 13,396
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 375 209 191 206 197
Adjusted total debt 20,645 16,047 14,480 14,456 7,068
Adjustments to Equity
Less: Net deferred tax asset (liability)2 (2,729) (1,304) 138 (312) (619)
Add: Allowance for doubtful accounts 16 16 15 18 21
Add: Deferred revenue 146 109 83 91 56
Adjusted stockholders’ equity 9,052 8,350 6,560 6,340 7,220
After Adjustment
Adjusted total capital 29,697 24,397 21,040 20,796 14,289

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Net deferred tax asset (liability). See details »


The capitalization structure exhibits a significant expansion from 2014 to 2018, primarily driven by a substantial increase in debt obligations. While reported total capital grew from US$ 13,396 million to US$ 26,431 million, the adjusted capital figures indicate a more aggressive expansion of the capital base, reaching US$ 29,697 million by the end of 2018.

Debt Obligations Trend
A consistent upward trajectory is observed in both reported and adjusted debt. Total reported debt increased from US$ 6,872 million in 2014 to US$ 20,270 million in 2018, representing a nearly threefold increase. Adjusted debt closely mirrored this growth, maintaining a consistent premium over reported figures across the five-year period.
Equity Divergence
A notable divergence exists between reported stockholders' equity and adjusted stockholders' equity. Reported equity remained relatively stagnant and experienced a slight net decline, ending 2018 at US$ 6,161 million compared to US$ 6,525 million in 2014. Conversely, adjusted stockholders' equity demonstrated a steady upward trend from 2015 onward, increasing from US$ 6,340 million to US$ 9,052 million by 2018.
Capitalization Adjustment Impact
The variance between reported and adjusted total capital widened progressively over the analyzed period. The adjustment gap grew from US$ 893 million in 2014 to US$ 3,266 million in 2018. This indicates that the adjustments made to the capitalization table became increasingly material over time, particularly through the upward adjustment of equity values, which offset the reported decline in stockholder equity.

AI Ask an analyst for more


Adjustments to Revenues

Celgene Corp., adjusted net product sales

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Net product sales 15,265 12,973 11,185 9,161 7,564
Adjustment
Add: Increase (decrease) in deferred revenue 37 26 (8) 34 5
After Adjustment
Adjusted net product sales 15,302 12,999 11,177 9,195 7,569

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).


A consistent and significant upward trajectory in revenue is observed from 2014 through 2018. Both reported net product sales and adjusted net product sales exhibit strong annual growth, with total revenue figures effectively doubling over the five-year period.

Growth Trends in Net Product Sales
Net product sales increased from 7,564 million US$ in 2014 to 15,265 million US$ in 2018. The most rapid acceleration was observed between 2014 and 2016, followed by a sustained growth rate of approximately 16% to 18% in the subsequent two years.
Growth Trends in Adjusted Net Product Sales
Adjusted net product sales mirrored the primary revenue trend, increasing from 7,569 million US$ in 2014 to 15,302 million US$ in 2018. The trajectory remains nearly identical to the unadjusted figures, indicating that the drivers of growth are consistent across both reporting metrics.
Analysis of Revenue Adjustments
The variance between net product sales and adjusted net product sales is immaterial. The absolute difference fluctuates between a maximum of 37 million US$ in 2018 and a minimum of -8 million US$ in 2016. These adjustments represent a negligible percentage of total revenue, suggesting that the adjustments do not significantly impact the overall financial performance profile or the interpretation of organic revenue growth.

AI Ask an analyst for more


Adjustments to Reported Income

Celgene Corp., adjusted net income

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Net income 4,046 2,940 1,999 1,602 2,000
Adjustments
Add: Deferred income tax expense (benefit)1 32 (1,330) (344) (33) (272)
Add: Increase (decrease) in allowance for doubtful accounts — 1 (3) (3) (7)
Add: Increase (decrease) in deferred revenue 37 26 (8) 34 5
Add: Other comprehensive income (loss) 233 (102) (349) (147) 821
After Adjustment
Adjusted net income 4,348 1,535 1,296 1,453 2,546

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Deferred income tax expense (benefit). See details »


Net income exhibited a general upward trajectory over the five-year period, characterized by a recovery from a mid-period dip. After a decrease in 2015, reported earnings grew consistently from 2016 through 2018, more than doubling from US$1,999 million in 2016 to US$4,046 million by the end of 2018.

Adjusted net income displayed more pronounced volatility and a different directional pattern than reported net income. A sustained decline was observed between 2014 and 2016, after which a recovery began, culminating in a sharp increase in 2018 to a period high of US$4,348 million.

Reported Net Income Performance
Profitability showed resilience, moving from US$2,000 million in 2014 to a peak of US$4,046 million in 2018. The growth between 2016 and 2018 was particularly aggressive, indicating a strong expansion in reported bottom-line results.
Adjusted Net Income Volatility
A downward trend occurred in the early part of the period, with values falling from US$2,546 million in 2014 to a low of US$1,296 million in 2016. This was followed by a significant rebound, particularly in 2018, where adjusted income grew by approximately 183% compared to the previous year.
Comparative Variance Analysis
The divergence between reported and adjusted net income fluctuated significantly. In 2014 and 2018, adjusted net income was higher than reported net income, suggesting the exclusion of non-recurring expenses or the inclusion of non-operating gains. However, from 2015 to 2017, reported net income exceeded adjusted net income, with the most substantial gap occurring in 2017, where reported income was US$1,405 million higher than the adjusted figure.

AI Ask an analyst for more